98%
921
2 minutes
20
Among the concepts in biology that are widely taken granted is a potentiated cooperative effect of multiple miRNAs on the same target. This strong hypothesis contrasts insufficient experimental evidence. The quantity as well as the quality of required side constraints of cooperative binding remain largely hidden. For miR-21-5p and miR-155-5p, two commonly investigated regulators across diseases, we selected 15 joint target genes. These were chosen to represent various neighboring 3'UTR binding site constellations, partially exceeding the distance rules that have been established for over a decade. We identified different cooperative scenarios with the binding of one miRNA enhancing the binding effects of the other miRNA and vice versa. Using both, reporter assays and whole proteome analyses, we observed these cooperative miRNA effects for genes that bear 3'UTR binding sites at distances greater than the previously defined limits. Astonishingly, the experiments provide even stronger evidence for cooperative miRNA effects than originally postulated. In the light of these findings the definition of targetomes specified for single miRNAs need to be refined by a concept that acknowledges the cooperative effects of miRNAs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875415 | PMC |
http://dx.doi.org/10.1186/s11658-023-00421-4 | DOI Listing |
BMC Genomics
September 2025
Applied Bioinformatics Group, Institute of Cell Biology and Neuroscience, Goethe University, Frankfurt, Germany.
Background: The regulatory network that coordinates gene expression ultimately determines the phenotype of an organism. Micro-RNAs (miRNAs) are post-transcriptional regulators involved in key biological processes. Lineage-specific losses of multiple miRNA families are rare, and reported cases of multiple miRNA losses coincide with significant changes in gene regulation resulting in body plan modifications.
View Article and Find Full Text PDFLancet
August 2025
Université de Lorraine, Inserm CIC 1433, CHRU, Nancy, France.
Background: Vericiguat is indicated to reduce the risk of cardiovascular death and hospitalisation for heart failure in patients with heart failure and reduced ejection fraction (HFrEF) following a recent worsening event. The aim of the VICTOR trial was to assess the effect of vericiguat in patients with HFrEF without recent heart failure worsening.
Methods: In this double-blind, placebo-controlled, phase 3 trial, conducted at 482 sites across 36 countries, patients aged 18 years or older with HFrEF (left ventricular ejection fraction of ≤40%) without heart failure hospitalisation within 6 months or outpatient intravenous diuretic use within 3 months before randomisation were randomly assigned (1:1) using an intervention randomisation system with interactive response technology to oral vericiguat (target 10 mg dose) or matching placebo.
Lancet
August 2025
Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
Background: Following completion of the VICTORIA trial, vericiguat was approved for the treatment of worsening heart failure with reduced ejection fraction (HFrEF) and received a class IIb recommendation in European and North American guidelines. The subsequent VICTOR trial evaluated the use of vericiguat in patients with HFrEF and no recent worsening. We aimed to assess the effect of vericiguat on clinical endpoints through pooled analyses of patient-level data from the VICTORIA and VICTOR trials.
View Article and Find Full Text PDFCrit Rev Oncol Hematol
August 2025
Afliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China. Electronic address:
The t(8;21) acute myeloid leukemia (AML) is driven by the AML1-ETO (AE) fusion protein formed through the translocation of chromosomes 8 and 21, which mediates AML malignant transformation via epigenetic reprogramming and cooperative genetic events. This review comprehensively delineates the molecular pathogenesis of the disease, emphasizing that splice isoforms such as AE9a acquire enhanced leukemogenic potential due to the loss of critical structural domains. Emerging evidence demonstrates that epigenetic dysregulation-including aberrant DNA methylation, dysregulated histone modifications, and non-coding RNA-mediated regulatory networks-synergizes with AE to orchestrate leukemogenesis.
View Article and Find Full Text PDFJ Neurochem
September 2025
Peritz Scheinberg Cerebral Vascular Disease Research Laboratories, University of Miami Leonard M. Miller School of Medicine, Miami, Florida, USA.
Nuclear factor erythroid 2-related factor 2 (Nrf2) plays a pivotal role as a transcription factor at the heart of cellular defense mechanisms against oxidative stress, orchestrating a suite of cytoprotective genes. This review places particular emphasis on the interplay between Nrf2 and Sirtuins-NAD-dependent deacetylases integral to redox regulation, metabolic control, and neuroprotection. We highlight how these proteins cooperate to regulate oxidative defense and cellular metabolism, with a particular focus on brain physiology and resilience.
View Article and Find Full Text PDF